Literature DB >> 27825415

Comparison of Sedative Effects of Two Spray Administration of Intranasal Dexmedetomidine Doses for Premedication in Children.

Jin Xu1, Xiao-Ming Deng1, Dong Yang1, Ling-Xin Wei1, Juan Zhi1, Wen-Li Xu1, Ju-Hui Liu1.   

Abstract

Objective To compare two spray administration of intranasal dexmedetomidine (DEX) doses for premedication in children. Methods In this prospective,randomized,double-blind study,41 children aged 3-6 years were enrolled. Children were assigned to receive either spray administration of intranasal DEX 1 μg/kg (Group D1) or 2 μg/kg (Group D2). The Ramsay Sedation Scale scores were evaluated at 5 min intervals. Sedation status at separation from patient was also evaluated. Heart rate (HR) and saturation of peripheral oxygen (SpO2) were recorded before and every 15 min after drug administration. Results The median sedation onset time was 30 min and 20 min in group D1 and group D2,respectively. Compared with the children in group D1,those in group D2 were significantly more sedated when they were separated from their parents (61.9% vs. 95.0%,respectively)(χ2=5.549,P=0.010). In Group D2,the HR decreased by 15.8% (t=2.415,P=0.021) 30 min after the spray administration of intranasal DEX. Compared with the baseline values,there was no significant difference in both groups in terms of SpO2(t=-1.426,P=0.162;t=-1.096,P=0.280)and HR in group D1 (t=-0.299,P=0.767) 30 min after the spray administration of intranasal DEX. Conclusion Spray administration of intranasal DEX 2 μg/kg provides superior sedation in children.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27825415     DOI: 10.3881/j.issn.1000-503X.2016.05.013

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  1 in total

1.  The Sedative Effects of Inhaled Nebulized Dexmedetomidine on Children: A Systematic Review and Meta-Analysis.

Authors:  Jun Lin; Chujun Wu; Dizhou Zhao; Xuhang Du; Wangzhi Zhang; Jieyu Fang
Journal:  Front Pediatr       Date:  2022-05-20       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.